Pannexin 1 Inhibitor
Pannexin 1 Inhibitor - Related Videos
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
0 Views •
Cited by 2 •
2024
This study illustrates the methodological potential of combining Yttrium-90 Trans-Arterial Radioembolization (Y-90 TARE) with an anti-PD-1 monoclonal antibody as an effective neoadjuvant strategy leading to hepatectomy in hepatocellular carcinoma (HCC) patients with a high initial recurrence risk. It emphasizes the safety, feasibility, and step-by-step procedural guidance of this approach.
07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
0 Views •
2025
This protocol describes a blockade assay for PD-1/PD-L1 inhibitors using surface plasmon resonance technology. It employs a dual-step immobilization strategy and a tailored buffer system to accurately measure response units, facilitating the assessment of blockade rates for compounds or biologics. Additionally, it supports the high-throughput identification of PD-1/PD-L1 inhibitors.
08:33
Nucleocapsid Annealing-Mediated Electrophoresis (NAME) Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors
0 Views •
Cited by 8 •
2015
This protocol describes NAME, an assay that allows the rapid identification of molecules able to inhibit in vitro the chaperone activities of HIV-1 nucleocapsid protein.
07:22
A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
0 Views •
Cited by 7 •
2018
We describe a cell-based assay to report on HIV-1 fusion via the expression of green fluorescent protein detectable by flow cytometry or fluorescence microscopy. It can be used to test inhibitors of viral entry (specifically at the fusion step) in cell-free and cell-to-cell infection systems.
01:52
Eukaryotic Transcription Inhibitors
0 Views •
2020
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells. Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
FAQs
Reducing pannexin 1 channel opening can limit the movement of ATP from cells into the extracellular environment. This changes the availability of an important signaling molecule outside the cell and allows investigators to examine how extracellular purinergic communication contributes to inflammatory responses, rather than treating those responses as independent of channel activity.
ATP can function as an extracellular signal that helps connect cellular activity with surrounding immune responses. When an inhibitor reduces ATP passage associated with pannexin 1 activity, researchers can assess whether changes in inflammation or host response are linked to altered purinergic communication. This makes ATP-related signaling a useful mechanistic focus in infection research.
The inhibitor provides a pharmacological comparison in which pannexin 1 activity is reduced while the broader experimental system remains under study. If an inflammatory or host-response feature changes under this condition, researchers can evaluate whether pannexin 1-dependent signaling contributes to it. The approach therefore helps separate channel-related effects from mechanisms that do not require pannexin 1.
Researchers can compare immune or infection-related responses in the presence and absence of the inhibitory agent. Interpreting the resulting differences requires attention to the specific response being measured, such as inflammatory pathway activity or host-cell behavior. These comparisons help determine whether the observed process is sensitive to reduced pannexin 1 signaling rather than merely associated with it.
This tool is useful when investigators want to test whether pannexin 1 participates in an inflammatory pathway, an infection-related host response, or purinergic communication between cells and their surroundings. It can also support studies of disease mechanisms by showing whether reducing channel activity changes the response under investigation, making the channel a more specific experimental focus.
Results can indicate whether modulating pannexin 1 has a meaningful relationship to inflammatory or infectious disease mechanisms. A response to inhibition may support further investigation of the channel as a therapeutic target, while little or no change can suggest that the pathway is not central in that context. These agents are therefore research tools for evaluating therapeutic possibilities, not conclusions by themselves.